Estée Lauder Companies
EL
$96.34
+3.11%
The Estée Lauder Companies is a global leader in the prestige beauty market, operating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and other categories (5%), with a portfolio that includes Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The company distributes through department stores, travel retail, specialty beauty retailers, freestanding stores, e-commerce, salons/spas, and perfumeries across more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe/Middle East/Africa (including travel retail), and 32% from Asia-Pacific. The current investor narrative centers on a turnaround story: after a prolonged period of earnings pressure and restructuring charges, the company is showing signs of accelerating sales and expanding margins, with management walking away from merger talks with Puig to pursue an independent plan. The August 2026 stock surge reflects growing conviction that the turnaround is working, though the company still faces a highly competitive beauty landscape and lingering margin recovery challenges.…
EL
Estée Lauder Companies
$96.34
Related headlines
Investment Opinion: Should I buy EL Today?
The synthesized recommendation is Hold. The core thesis is that Estée Lauder is a credible turnaround story with improving fundamentals, but the valuation already reflects much of the near-term recovery, and significant execution risks remain. The analyst consensus rating of 'buy' with an average target price of $107.04 implies 14.6% upside, but the wide target range of $70 to $127 underscores high uncertainty. The stock is not a compelling buy at current levels given the margin and debt challenges.
Supporting evidence for a Hold includes: revenue growth of 4.56% year-over-year in Q3 FY2026, a swing to positive net income of $89 million, and free cash flow of $1.285 billion. The forward PE of 23.87x is reasonable if EPS reaches $4.25, but the trailing PE of 157.9x and EV/EBITDA of 40.37x are stretched. The gross margin of 75.5% remains above the industry average, but the net margin of 1.21% is well below peers. The dividend yield of 1.78% is attractive, but the payout ratio of 279% is unsustainable. Relative to its own history, the PS ratio of 1.90x is near multi-year lows, suggesting the stock is not expensive on a sales basis.
The biggest risks that could invalidate the thesis are: (1) a failure to sustain margin recovery, with operating margin stuck below 7%; (2) a downturn in travel retail or Asia-Pacific that reverses revenue growth; and (3) a dividend cut due to the unsustainable payout ratio. The rating would upgrade to Buy if operating margins exceed 10% for two consecutive quarters and revenue growth accelerates above 6%, or if the stock pulls back to the $75-$80 range. It would downgrade to Sell if revenue growth turns negative or if operating margins fail to improve from 5.18%. The stock appears fairly valued relative to its history and peers, with a slight premium justified only by the recovery potential.
Sign up to view all
EL 12-Month Price Forecast
Estée Lauder is at an inflection point, with early signs of a successful turnaround but substantial risks remaining. The forward valuation is reasonable if earnings recover as expected, but the company must demonstrate sustained margin improvement and revenue acceleration to justify a higher rating. The analyst consensus is cautiously optimistic, but the wide target range reflects uncertainty. I would upgrade to bullish if operating margins exceed 10% for two consecutive quarters and revenue growth accelerates above 6%. I would downgrade to bearish if revenue growth turns negative or if operating margins fail to improve from current levels. The risk/reward is balanced, favoring a neutral stance until more evidence of a durable recovery emerges.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $107.04 and implied upside of +11.1% versus the current price.
Average Target
$107.04
0 analysts
Implied Upside
+11.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $127
Analyst target range
The stock is covered by 27 analysts, with a consensus recommendation of "buy" and an average target price of $107.04. This implies upside of approximately 14.6% from the current price of $93.43. The recommendation mean of 2.31 (on a scale where 1 is strong buy and 5 is strong sell) leans bullish, but the distribution of ratings shows a mix of buy, hold, and equal weight ratings, indicating that not all analysts are convinced. The consensus EPS estimate for the next fiscal year is $4.25, with a range of $4.02 to $4.35, and estimated revenue averages $17.854 billion.
The target price range is wide, from a low of $70 to a high of $127, reflecting significant uncertainty about the company's future. The high target of $127 assumes a full recovery in margins and accelerating growth, potentially driven by successful execution of the turnaround plan and a rebound in travel retail and Asia. The low target of $70 prices in continued margin compression, competitive pressures, and a slower-than-expected recovery. Recent institutional ratings show a mix of actions: Citigroup and JP Morgan maintain Buy/Overweight ratings, while Barclays, Wells Fargo, UBS, and others have Equal Weight/Neutral/Hold ratings. The wide spread between the high and low targets signals high uncertainty, and the lack of recent upgrades suggests that analysts are waiting for more evidence of a sustained turnaround before turning more bullish.
Bulls vs Bears: EL Investment Factors
The bull case rests on a credible turnaround: three consecutive quarters of positive net income, 4.56% revenue growth, and a forward PE of 23.87x that prices in an earnings recovery. The bear case highlights that margins remain far below historical levels, debt is high at 2.43x debt-to-equity, and the stock has significantly underperformed the market. Currently, the bear evidence appears slightly stronger because the recovery is still early and the valuation on trailing metrics is stretched, but the forward outlook is more balanced. The single most important tension is whether the margin recovery can be sustained; if operating margins return to the 10-15% range, the stock could re-rate substantially, but failure to do so would likely lead to further multiple compression.
Bullish
- Turnaround gains traction with positive earnings: EL swung from a net loss of $546 million in Q4 FY2025 to positive net income in each of the last three quarters, including $89 million in Q3 FY2026. This reversal demonstrates that management's restructuring and cost-control efforts are yielding tangible results.
- Revenue growth accelerating modestly: Q3 FY2026 revenue rose 4.56% year-over-year to $3.712 billion, with sequential improvement from $3.481 billion in Q1 to $4.238 billion in Q2. The upward trend suggests the core business is stabilizing despite headwinds in travel retail and Asia-Pacific.
- Forward valuation reasonable if recovery holds: The forward PE of 23.87x is far more palatable than the trailing PE of 157.9x, implying the market expects EPS to jump to $4.25 next fiscal year. This multiple is in line with consumer defensive peers, offering upside if earnings materialize.
- Strong free cash flow and improving cash generation: Trailing twelve-month free cash flow stands at $1.285 billion, and operating cash flow rebounded to $412 million in Q3 FY2026 from negative $340 million in Q1. This provides ample liquidity to fund the turnaround and maintain the dividend.
Bearish
- Margins remain well below historical norms: Trailing twelve-month operating margin is just 5.18% and net margin 1.21%, far below the company's historical 10-15% operating margin range. Gross margin also declined to 71.04% in Q3 FY2026 from 74.96% a year earlier, indicating persistent cost pressures.
- Elevated debt burden constrains flexibility: Debt-to-equity stands at 2.43x, and the current ratio of 1.22 is only adequate. Interest expense of $82 million per quarter consumes a significant portion of operating income, limiting reinvestment capacity and increasing vulnerability if the turnaround stalls.
- Unsustainable dividend payout ratio: The payout ratio of 279% on trailing earnings is clearly unsustainable without continued earnings recovery. While the dividend yield of 1.78% is attractive, it could be at risk if profitability does not improve as expected.
- Relative underperformance versus the market: EL has lagged the S&P 500 by 8.84% over the past year and 24.19% year-to-date, despite a 6.17% absolute gain. This persistent underperformance suggests the market remains skeptical about the sustainability of the turnaround.
EL Technical Analysis
Estée Lauder is in a recovery uptrend that has been choppy over the past year. The stock is up 6.17% over the trailing 12 months, but that masks a wide swing: it hit a 52-week low of $66.22 and a high of $121.64, with the current price of $93.43 sitting at roughly 49% of that range. That mid-range positioning suggests the stock is neither overextended nor deeply discounted, but it does reflect a market that has not fully committed to the turnaround story. The YTD decline of 12.49% also indicates that the recovery has been uneven and that the stock has not yet reclaimed its early-2026 highs.
Short-term momentum has turned negative even as the longer-term trend remains positive. The stock is down 4.67% over the past month, which contrasts with a 10.16% gain over the past three months and an 8.74% gain over six months. This divergence suggests a temporary pullback within a broader recovery, but the recent weakness is notable: the stock fell from a high of $106.21 on August 27 to $93.43 by September 18, a decline of roughly 12% in just over three weeks. Relative strength versus the S&P 500 is negative over the past month (-3.71%) and over the past year (-8.84%), indicating the stock has lagged the broader market despite its absolute gains.
Key technical levels are well defined. The 52-week low of $66.22 represents major support, while the 52-week high of $121.64 is the primary resistance level. A breakout above $121.64 would signal a full recovery and likely attract momentum buyers, while a breakdown below $66.22 would suggest the turnaround narrative is failing. The stock's beta of 1.274 means it is roughly 27% more volatile than the S&P 500, which is important for position sizing: a 10% market move could translate to a 12.7% move in EL. The current price of $93.43 is about 41% above the 52-week low and 23% below the 52-week high, placing it in a neutral technical zone with room to move in either direction.
Beta
1.27
1.27x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
+9.7%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +1.0% |
| 3m | +15.0% | +5.4% |
| 6m | +31.8% | +17.8% |
| 1y | +9.7% | +16.5% |
| ytd | -9.8% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Revenue has been growing modestly but consistently. The most recent quarter (Q3 FY2026, ended March 31, 2026) reported revenue of $3.712 billion, up 4.56% year-over-year from $3.55 billion in the prior-year quarter. Sequentially, revenue has improved from $3.481 billion in Q1 FY2026 to $4.238 billion in Q2 FY2026 and $3.712 billion in Q3 FY2026, showing typical seasonality but also a clear upward trend in the underlying business. The skin care segment is the largest contributor at $1.856 billion, followed by makeup at $1.072 billion, fragrance at $628 million, and hair care at $128 million. The growth trajectory is encouraging but not explosive, and the company still faces headwinds in travel retail and Asia-Pacific, which have been drags on overall performance.
Profitability has improved significantly from the prior year, though margins remain below historical peaks. Net income in Q3 FY2026 was $89 million, a sharp reversal from the $159 million loss in Q3 FY2025, and gross margin came in at 71.04%, down from 74.96% in the prior-year quarter but still healthy for the industry. Operating margin was 9.64% in Q3 FY2026, up from 8.62% a year earlier, and net margin was 2.40%, up from 4.48% in the prior-year quarter (which included a one-time gain). The company swung from a net loss of $546 million in Q4 FY2025 to positive net income in each of the last three quarters, demonstrating that the turnaround is gaining traction. However, the trailing twelve-month net margin of 1.21% and operating margin of 5.18% remain well below the company's historical norms of 10-15% operating margins, indicating there is still substantial room for improvement.
The balance sheet carries meaningful leverage, but cash generation is improving. Debt-to-equity stands at 2.43x, and the current ratio is 1.22, which is adequate but not strong. Free cash flow on a trailing twelve-month basis is $1.285 billion, and the company generated $412 million in operating cash flow in Q3 FY2026 alone, up from negative $340 million in Q1 FY2026. The company paid $126 million in dividends in Q3 FY2026, and the payout ratio of 279% on trailing earnings is unsustainable if earnings do not continue to recover. ROE is just 4.78%, reflecting the depressed earnings base, but the improving cash flow and the company's ability to fund growth internally are positive signs. The debt load remains a risk, particularly if the turnaround stalls.
Quarterly Revenue
$3.7B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
71.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
Because Estée Lauder is profitable on a trailing basis (net income of $89 million in the most recent quarter), the PE ratio is the primary metric. The trailing PE is 157.9x, which is extremely elevated and reflects the depressed earnings base rather than a premium valuation. The forward PE is 23.87x, based on estimated EPS of $4.25 for the next fiscal year, which is far more reasonable and suggests the market expects a substantial earnings recovery. The gap between the trailing and forward PE is enormous, implying that investors are pricing in a sharp rebound in profitability over the next 12 months.
Compared to the broader household and personal products industry, Estée Lauder trades at a premium on most metrics. The price-to-sales ratio is 1.90x, and the price-to-book ratio is 7.52x, both of which are elevated relative to the sector. The EV/EBITDA of 40.37x is also very high, reflecting the current low EBITDA base. However, the forward PE of 23.87x is more in line with the sector average for consumer defensive names, suggesting that the premium is justified only if the earnings recovery materializes. The company's gross margin of 75.5% is above the industry average, which supports a premium valuation, but the net margin of 1.21% is well below peers, highlighting the operational challenges.
Historically, Estée Lauder's valuation has been much higher. The PE ratio was above 40x in 2021 and 2022, and the PS ratio was above 20x during the pandemic-era boom. The current PS ratio of 1.90x is near the low end of its historical range, while the PB ratio of 7.52x is also below its historical average of 10-15x. This suggests that the stock is trading at a discount to its own history, which could represent a value opportunity if the turnaround continues. However, the low valuation also reflects the market's skepticism about the sustainability of the recovery, and the stock could remain cheap if earnings fail to accelerate.
PE
157.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 28x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
40.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company carries a debt-to-equity ratio of 2.43x and a current ratio of just 1.22, leaving limited cushion if earnings falter. Interest expense of $82 million per quarter consumes a large share of operating income, and the trailing twelve-month net margin of 1.21% is razor-thin. The dividend payout ratio of 279% is unsustainable without continued earnings growth, and any stall in the recovery could force a dividend cut or further balance sheet deterioration. Additionally, revenue concentration in skin care (49% of sales) and reliance on travel retail and Asia-Pacific (32% of revenue) expose the company to regional economic downturns and geopolitical disruptions.
Market and competitive risks are equally concerning. EL trades at a premium on most valuation metrics: price-to-book of 7.52x, EV/EBITDA of 40.37x, and price-to-sales of 1.90x. These multiples leave little room for error, and any earnings miss could trigger sharp multiple compression. The prestige beauty market is highly competitive, with nimble indie brands and larger rivals like L'Oréal gaining share. The stock's beta of 1.274 means it is 27% more volatile than the S&P 500, amplifying market downturns. Recent news highlights the company's decision to walk away from merger talks with Puig, which removes a potential near-term catalyst and puts full pressure on the standalone turnaround plan.
In a worst-case scenario, a global recession or a slowdown in China and travel retail could cause revenue to decline, reversing the recent growth. Margins could compress further if promotional activity intensifies, and the company might be forced to cut its dividend to preserve cash. The stock could retest its 52-week low of $66.22, representing a 29% decline from the current price of $93.43. The analyst low target of $70 implies a 25% downside. Given the max drawdown of 43.79% over the past year, a similar decline from current levels would take the stock to around $52.50, though that is an extreme scenario. More realistically, a failure of the turnaround could see the stock fall to the $70-$75 range, a loss of 20-25%.
FAQ
The key risks include: (1) Financial risk: high debt-to-equity of 2.43x and an unsustainable dividend payout ratio of 279%, which could lead to a dividend cut. (2) Operational risk: margins remain depressed, with TTM operating margin of 5.18% versus historical 10-15%, and any failure to improve could stall the turnaround. (3) Competitive risk: intense competition in prestige beauty from L'Oréal and indie brands could erode market share. (4) Macro risk: beta of 1.274 means the stock is more volatile than the market, and a global recession could reduce discretionary spending on beauty products. These risks are ranked from most to least severe.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $120-$127, assuming successful margin recovery and revenue acceleration. Base case (55% probability) targets $100-$110, with steady growth and margin improvement to 7-8%. Bear case (20% probability) targets $66-$75, if the turnaround stalls and revenue declines. The base case is most likely, hinging on operating margin reaching 7-8% and revenue growth of 4-5%. The analyst average target of $107.04 aligns with our base case.
EL appears fairly valued on a forward basis but overvalued on trailing metrics. The forward PE of 23.87x is in line with consumer defensive peers, suggesting the market is pricing in an earnings recovery. However, the price-to-book ratio of 7.52x and EV/EBITDA of 40.37x are high relative to history and peers. The PS ratio of 1.90x is near multi-year lows, indicating the stock is not expensive on a sales basis. Overall, the valuation implies the market expects a successful turnaround; if that fails, the stock could be significantly overvalued.
EL is a moderate buy for investors with a higher risk tolerance and a long-term horizon. The stock trades at $93.43, with analyst targets averaging $107.04, implying 14.6% upside. The forward PE of 23.87x is reasonable if earnings recover to $4.25 per share, but the trailing PE of 157.9x and EV/EBITDA of 40.37x are elevated. The biggest downside risk is a failure of the turnaround, which could send the stock back to its 52-week low of $66.22, a 29% decline. For those willing to accept volatility, the risk/reward is balanced, but it is not a screaming buy at current levels.
EL is more suitable for long-term investment (minimum 2-3 years) given its turnaround nature and high volatility (beta 1.274). The company is in the early stages of a recovery, and it may take several quarters for margins to normalize. Short-term trading is risky due to earnings volatility and the wide analyst target range. The dividend yield of 1.78% provides some income, but the payout ratio is unsustainable, so income investors should be cautious. A long-term horizon allows time for the turnaround to fully materialize and for the stock to potentially re-rate.